Eyenovia to discontinue late-stage study for eye drug-March 2024-www.financetom.com

Eyenovia to discontinue late-stage study for eye drug

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Eyenovia to discontinue late-stage study for eye drug

Nov 15, 2024 12:25 PM

Nov 15 (Reuters) - Eyenovia ( EYEN ) said on Friday it

would terminate a late-stage study testing its experimental

drug-device combination for pediatric progressive myopia as it

failed to meet the main goal.

Previous page： Google agrees $36 million fine for anti-competitive deals with Australia telcos Next page： ASX-listed James Hardie secures $3.5 billion senior credit facilities

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Google agrees $36 million fine for anti-competitive deals with Australia telcos

Aug 17, 2025

SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...

ASX-listed James Hardie secures $3.5 billion senior credit facilities

Jun 1, 2025

June 2 (Reuters) - ASX-listed James Hardie said on Monday it had secured new senior credit facilities for a total of $3.5 billion with broad support, including 30 participating banks to support its operations and acquisition of U.S.-listed AZEK ( AZEK ). ...

KKR raises conditional offer for German IT services firm Datagroup

Jun 1, 2025

(Reuters) -Frankfurt-listed IT services provider Datagroup SE said on Sunday that KKR has made a conditional proposal to increase the potential acquisition offer to up to 58 euros ($65.84) per share. KKR initially offered 54 euros per share in an all-cash transaction valuing Datagroup at approximately 450 million euros. Under the revised terms, the offer price will rise to 56.50...

23andMe founder aims to restart auction with major corporate backing

Jun 1, 2025

June 1 (Reuters) - The founder of 23andMe, Anne Wojcicki, has asked a U.S. judge to reopen an auction for the genetic testing company, saying she has the support of a Fortune 500 company with a current market capitalization of more than $400 billion. Wojcicki did not name the Fortune 500 company in court filings. South San Francisco, California-based 23andMe...